Seattle Genetics (SGEN) Getting Somewhat Favorable News Coverage, Accern Reports

Media headlines about Seattle Genetics (NASDAQ:SGEN) have been trending somewhat positive recently, Accern reports. The research group identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Seattle Genetics earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 46.3532414246096 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Here are some of the media headlines that may have effected Accern Sentiment Analysis’s analysis:

Several equities analysts have commented on the company. Barclays PLC upgraded Seattle Genetics from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $60.00 to $70.00 in a report on Friday, October 20th. Zacks Investment Research downgraded Seattle Genetics from a “buy” rating to a “hold” rating in a report on Monday, October 16th. Guggenheim reiterated a “buy” rating and set a $72.00 price target on shares of Seattle Genetics in a report on Monday, October 23rd. Jefferies Group LLC reiterated a “buy” rating and set a $53.00 price target on shares of Seattle Genetics in a report on Thursday. Finally, Bank of America Corporation upgraded Seattle Genetics from an “underperform” rating to a “neutral” rating in a report on Friday. Two analysts have rated the stock with a sell rating, thirteen have given a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $61.65.

Seattle Genetics (NASDAQ SGEN) opened at 62.73 on Friday. Seattle Genetics has a 12 month low of $45.31 and a 12 month high of $75.36. The company has a 50-day moving average price of $57.04 and a 200 day moving average price of $57.64. The company’s market capitalization is $8.97 billion.

Seattle Genetics (NASDAQ:SGEN) last issued its quarterly earnings results on Thursday, October 26th. The biotechnology company reported ($0.19) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.42) by $0.23. The business had revenue of $135.29 million for the quarter, compared to analyst estimates of $112.76 million. Seattle Genetics had a negative return on equity of 33.16% and a negative net margin of 26.53%. Seattle Genetics’s quarterly revenue was up 27.3% compared to the same quarter last year. During the same period last year, the company posted ($0.23) earnings per share. On average, equities research analysts forecast that Seattle Genetics will post ($1.69) EPS for the current fiscal year.

In other Seattle Genetics news, insider Vaughn B. Himes sold 10,000 shares of the firm’s stock in a transaction on Friday, September 8th. The stock was sold at an average price of $53.22, for a total value of $532,200.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Clay B. Siegall sold 18,832 shares of the firm’s stock in a transaction on Wednesday, October 11th. The stock was sold at an average price of $61.18, for a total value of $1,152,141.76. The disclosure for this sale can be found here. Insiders have sold 173,761 shares of company stock worth $8,949,050 over the last quarter. 34.70% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: This piece was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of international trademark and copyright law. The correct version of this piece can be accessed at

Seattle Genetics Company Profile

Seattle Genetics, Inc is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company’s marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC).

Insider Buying and Selling by Quarter for Seattle Genetics (NASDAQ:SGEN)

Receive News & Ratings for Seattle Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics Inc. and related companies with's FREE daily email newsletter.

Leave a Reply